Carlsbad, CA-based Isis Pharmaceuticals ($ISIS) nabbed a $7.5 million milestone payment from GlaxoSmithKline ($GSK) on the launch of a Phase II/III clinical study for ISIS-TTR, an antisense drug in development for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and heart tissues. Release